Developer docs
API playgroundTry for free, no card

Search company profiles

Wellsense

Full company profile

uuid0000fhg

Namestring
Wellsense
Legal namestring
Wellsense, Inc.
Websiteurl
wellsensevu.com
Company typeenum
Private
Founded yearint
2009
Descriptiontext

Wellsense, Inc. is a private medical device company founded in 2009 and headquartered in Birmingham, Alabama. The company develops and manufactures the Wellsense Vū, an FDA-registered Class I real-time continuous bedside pressure monitoring and visualization system designed to detect and display pressure distribution on patient surfaces. The technology addresses the clinical problem of hospital-acquired pressure injuries (HAPIs) by giving nurses visual feedback on patient pressure states through a structured SEE-OFFLOAD-CONFIRM workflow: assess present pressure, review past pressure patterns via 2-hour video feedback compression, and ensure future pressure management with optional EMR integration and voice input. The product is differentiated by what the company describes as the only pressure monitoring solution to qualify for meta-analysis after review of 1,866 published articles over 11 years, with an 88% reduction in pressure injury risk validated by a Johns Hopkins-led meta-analysis and outcomes published in peer-reviewed journals including Advances in Skin & Wound Care and BMJ Quality & Safety.

Wellsense operates an enterprise field sales motion targeting hospital clinical leadership, nursing management, and administrators across critical care units, burn units, long-term care facilities, and Veterans Health Administration sites. Named deployments include Johns Hopkins Burn Center, Henry Ford Hospital, University of Kansas Hospital Burnett Burn Center, Methodist Dallas Medical Center, Swedish Medical Center, Floyd Medical Center, Carl T. Hayden VA Medical Center, SSM DePaul Health Center, Villa Maria Care Center, and two UK NHS acute orthopedic trauma wards. The company is HIPAA and SOC2 compliant, supports an optional EMR integration with voice input, and markets primarily in the United States with a limited UK footprint.

The business model is centered on hardware sales of the Wellsense Vū device on a per-bed or per-unit basis, supplemented by a CapEx-free strategic deployment option that targets highest-risk patients within hospitals. Contracts are structured as multi-year agreements. Since 2011 the company has filed nine SEC Form D exempt securities offerings totaling approximately $21.9 million, with the most recent filing in March 2024 covering up to $6 million ($5.62 million sold). Leadership includes CEO Ron Ferber, founder Itai Arad, COO Mordechai Lev, and director Ran Poliakine. The company employs 11–50 people and remains in growth-investment mode rather than at scale.

Short descriptiontext

Wellsense is a private medical device company that develops the FDA-registered Wellsense Vū, a real-time continuous bedside pressure monitoring and visualization system designed to help hospitals prevent hospital-acquired pressure injuries in critical care, burn, and long-term care settings.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBirmingham, United States
HQ citystring
Birmingham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pressure monitoring systems, medical device manufacturing, pressure injury prevention, patient monitoring technology, hospital critical care equipment
Industry3 codes
PRIMARYHLAHAIAF
Infusion Pumps (Ambulatory/Stationary)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAKAB
Peritoneal Dialysis (PD) Systems & Supplies
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
Product category
Patient Monitoring Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Sale of Wellsense VŪ real-time pressure monitoring system as a Class I medical device to healthcare facilities. The device is deployed on a per-bed or per-unit basis targeting high-risk patients. CapEx-free deployment model available where the company provides the technology for strategic deployment in high-risk areas.

wellsensevu.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1CapEx-Free Strategic Deployment
ModelOtherBilling cadenceMulti-year contract
Notes

Deploy where it matters - directing limited budgets toward highest risk patients who typically drive most pressure injury costs. Every dollar aligned toward clinical and financial impact.

wellsensevu.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Wellsense develops and manufactures Wellsense Vū, a Class I FDA-registered real-time pressure monitoring medical device designed for hospital critical care settings. The system continuously measures interface pressure between patients and support surfaces (such as ICU beds) to help clinicians prevent pressure injuries (bedsores). The company targets acute care hospitals and intensive care units where immobilized patients are at high risk of pressure-related tissue damage.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 88% reduction in pressure injury risk (Johns Hopkins-led meta-analysis)
+4 more records
Product overview1 text field

Wellsense offers a single unified product: Wellsense VŪ, a real-time pressure monitoring and visually guided pressure offloading system. The product is a Class I medical device that gives nurses real-time visibility into patient pressure, enabling them to see pressure levels, offload with precision, and confirm that interventions were effective. The system includes features for assessing present pressure, reviewing past pressure through 2-hour video feedback, and ensuring future pressure management through EMR integration with voice input options.

Product and service1 record
1Wellsense Vū Pressure Monitoring System
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Bruin Biometrics manufactures the SEM Scanner, a hand-held sub-epidermal moisture scanner for early pressure injury detection. It is the most direct competitor to Wellsense Vū, targeting the same hospital PI-prevention use case with a point-in-time diagnostic rather than continuous monitoring.

TypeDirect peer
Description

Leaf Healthcare offers a wireless patient turning and mobility sensor system designed to prevent hospital-acquired pressure injuries through continuous monitoring of patient repositioning. Highly comparable to Wellsense on technology approach (continuous bedside monitoring) and target buyer (hospital nursing leadership).

TypeDirect peer
Description

EarlySense provides contact-free continuous patient monitoring (heart rate, respiratory rate, motion) for hospital beds, addressing patient safety events including falls and deterioration. Comparable as a continuous bedside sensor platform sold into the same hospital enterprise channel.

TypeBroad incumbent
Description

Mölnlycke is a global wound care leader with Mepilex Border and other PI-prevention dressings. It addresses the same HAPI problem with a different mechanism (advanced dressings vs. continuous monitoring) and competes for the same hospital wound-care budget.

TypeBroad incumbent
Description

Smith+Nephew's Advanced Wound Management portfolio (ALLEVYN, PICO) competes for hospital PI-prevention spend. A broad incumbent with deep hospital sales coverage; not a continuous-monitoring peer but competes for the same clinical and budgetary mindshare.

TypeBroad incumbent
Description

ConvaTec supplies wound and skin care products (including foam dressings) used in PI prevention and treatment. A broad incumbent serving the same hospital wound-care stakeholders that buy PI-prevention solutions.

TypeBroad incumbent
Description

3M's Health Care division includes wound management and skin integrity products used for pressure injury prevention. A massive incumbent with strong hospital procurement relationships; overlaps with Wellsense at the budget-allocation level.

TypeBroad incumbent
Description

Coloplast's Wound Care business offers dressings and skin care products used in pressure injury prevention and treatment. A broad incumbent serving similar clinical customers across U.S. and European hospital systems.

TypeBroad incumbent
Description

Baxter acquired Hillrom, whose Centrella and Progressa smart hospital beds integrate surface pressure sensing and turn-assist features. Competes with Wellsense at the hospital-bed level for capital budget and increasingly for connected-bed data.

TypeBroad incumbent
Description

Stryker's Medical division includes smart hospital beds (ProCuity, iBed) with integrated pressure redistribution and patient monitoring. A broad incumbent whose connected-bed strategy overlaps with Wellsense's bedside pressure monitoring thesis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Wellsense

Patient Monitoring Medical Deviceswellsensevu.com

Wellsense is a private medical device company that develops the FDA-registered Wellsense Vū, a real-time continuous bedside pressure monitoring and visualization system designed to help hospitals prevent hospital-acquired pressure injuries in critical care, burn, and long-term care settings.

What Wellsense does

Wellsense, Inc. is a private medical device company founded in 2009 and headquartered in Birmingham, Alabama. The company develops and manufactures the Wellsense Vū, an FDA-registered Class I real-time continuous bedside pressure monitoring and visualization system designed to detect and display pressure distribution on patient surfaces. The technology addresses the clinical problem of hospital-acquired pressure injuries (HAPIs) by giving nurses visual feedback on patient pressure states through a structured SEE-OFFLOAD-CONFIRM workflow: assess present pressure, review past pressure patterns via 2-hour video feedback compression, and ensure future pressure management with optional EMR integration and voice input. The product is differentiated by what the company describes as the only pressure monitoring solution to qualify for meta-analysis after review of 1,866 published articles over 11 years, with an 88% reduction in pressure injury risk validated by a Johns Hopkins-led meta-analysis and outcomes published in peer-reviewed journals including Advances in Skin & Wound Care and BMJ Quality & Safety.

Wellsense operates an enterprise field sales motion targeting hospital clinical leadership, nursing management, and administrators across critical care units, burn units, long-term care facilities, and Veterans Health Administration sites. Named deployments include Johns Hopkins Burn Center, Henry Ford Hospital, University of Kansas Hospital Burnett Burn Center, Methodist Dallas Medical Center, Swedish Medical Center, Floyd Medical Center, Carl T. Hayden VA Medical Center, SSM DePaul Health Center, Villa Maria Care Center, and two UK NHS acute orthopedic trauma wards. The company is HIPAA and SOC2 compliant, supports an optional EMR integration with voice input, and markets primarily in the United States with a limited UK footprint.

The business model is centered on hardware sales of the Wellsense Vū device on a per-bed or per-unit basis, supplemented by a CapEx-free strategic deployment option that targets highest-risk patients within hospitals. Contracts are structured as multi-year agreements. Since 2011 the company has filed nine SEC Form D exempt securities offerings totaling approximately $21.9 million, with the most recent filing in March 2024 covering up to $6 million ($5.62 million sold). Leadership includes CEO Ron Ferber, founder Itai Arad, COO Mordechai Lev, and director Ran Poliakine. The company employs 11–50 people and remains in growth-investment mode rather than at scale.

Wellsense firmographics

Firmographics
Name
Wellsense
Legal name
Wellsense, Inc.
Website
https://wellsensevu.com
Company type
Private
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Wellsense is a private medical device company that develops the FDA-registered Wellsense Vū, a real-time continuous bedside pressure monitoring and visualization system designed to help hospitals prevent hospital-acquired pressure injuries in critical care, burn, and long-term care settings.
Ownership category
akta.pro rank

Wellsense industry classification

Industry
Product category
Patient Monitoring Medical Devices
akta.pro industry
PRIMARYHLAHAIAF
Infusion Pumps (Ambulatory/Stationary)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAKAB
Peritoneal Dialysis (PD) Systems & Supplies
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Pressure monitoring systems
  • Medical device manufacturing
  • Pressure injury prevention
  • Patient monitoring technology
  • Hospital critical care equipment

Where Wellsense is headquartered

Location

Headquarters

HQ city
Birmingham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Wellsense business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Sales: Sale of Wellsense VŪ real-time pressure monitoring system as a Class I medical device to healthcare facilities. The device is deployed on a per-bed or per-unit basis targeting high-risk patients. CapEx-free deployment model available where the company provides the technology for strategic deployment in high-risk areas.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCapEx-Free Strategic Deployment

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Wellsense product offering

Product offering

Core offering

Wellsense develops and manufactures Wellsense Vū, a Class I FDA-registered real-time pressure monitoring medical device designed for hospital critical care settings. The system continuously measures interface pressure between patients and support surfaces (such as ICU beds) to help clinicians prevent pressure injuries (bedsores). The company targets acute care hospitals and intensive care units where immobilized patients are at high risk of pressure-related tissue damage.

Product overview

Wellsense offers a single unified product: Wellsense VŪ, a real-time pressure monitoring and visually guided pressure offloading system. The product is a Class I medical device that gives nurses real-time visibility into patient pressure, enabling them to see pressure levels, offload with precision, and confirm that interventions were effective. The system includes features for assessing present pressure, reviewing past pressure through 2-hour video feedback, and ensuring future pressure management through EMR integration with voice input options.

Differentiator

Problem solved

Functional benefit

Products and services

  • Wellsense Vū Pressure Monitoring System

Quantifiable outcome

  • 88% reduction in pressure injury risk (Johns Hopkins-led meta-analysis)
  • +4 more outcomes

Companies that use Wellsense

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles1 record

Wellsense technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Wellsense partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Wellsense competitors and assessment

Company assessment

Direct peers

  • Bruin Biometrics: Bruin Biometrics manufactures the SEM Scanner, a hand-held sub-epidermal moisture scanner for early pressure injury detection. It is the most direct competitor to Wellsense Vū, targeting the same hospital PI-prevention use case with a point-in-time diagnostic rather than continuous monitoring.
  • Leaf Healthcare: Leaf Healthcare offers a wireless patient turning and mobility sensor system designed to prevent hospital-acquired pressure injuries through continuous monitoring of patient repositioning. Highly comparable to Wellsense on technology approach (continuous bedside monitoring) and target buyer (hospital nursing leadership).
  • EarlySense: EarlySense provides contact-free continuous patient monitoring (heart rate, respiratory rate, motion) for hospital beds, addressing patient safety events including falls and deterioration. Comparable as a continuous bedside sensor platform sold into the same hospital enterprise channel.

Broad incumbents

  • Mölnlycke Health Care: Mölnlycke is a global wound care leader with Mepilex Border and other PI-prevention dressings. It addresses the same HAPI problem with a different mechanism (advanced dressings vs. continuous monitoring) and competes for the same hospital wound-care budget.
  • Smith+Nephew: Smith+Nephew's Advanced Wound Management portfolio (ALLEVYN, PICO) competes for hospital PI-prevention spend. A broad incumbent with deep hospital sales coverage; not a continuous-monitoring peer but competes for the same clinical and budgetary mindshare.
  • ConvaTec: ConvaTec supplies wound and skin care products (including foam dressings) used in PI prevention and treatment. A broad incumbent serving the same hospital wound-care stakeholders that buy PI-prevention solutions.
  • 3M Health Care: 3M's Health Care division includes wound management and skin integrity products used for pressure injury prevention. A massive incumbent with strong hospital procurement relationships; overlaps with Wellsense at the budget-allocation level.
  • Coloplast: Coloplast's Wound Care business offers dressings and skin care products used in pressure injury prevention and treatment. A broad incumbent serving similar clinical customers across U.S. and European hospital systems.
  • Baxter International (Hillrom): Baxter acquired Hillrom, whose Centrella and Progressa smart hospital beds integrate surface pressure sensing and turn-assist features. Competes with Wellsense at the hospital-bed level for capital budget and increasingly for connected-bed data.
  • Stryker: Stryker's Medical division includes smart hospital beds (ProCuity, iBed) with integrated pressure redistribution and patient monitoring. A broad incumbent whose connected-bed strategy overlaps with Wellsense's bedside pressure monitoring thesis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Wellsense social profiles

Digital presence

Wellsense compliance and trust

Trust signal

Compliance3 records

Wellsense financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Wellsense leadership team

Management profile

Number of profiles

Profiles4 records

Wellsense funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Wellsense M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellsense

What does Wellsense do?

Wellsense develops and manufactures Wellsense Vū, a Class I FDA-registered real-time pressure monitoring medical device designed for hospital critical care settings. The system continuously measures interface pressure between patients and support surfaces (such as ICU beds) to help clinicians prevent pressure injuries (bedsores). The company targets acute care hospitals and intensive care units where immobilized patients are at high risk of pressure-related tissue damage.

Is Wellsense a public or private company?

Wellsense is a private company. It is classified as venture growth investor backed and is currently operating.

When was Wellsense founded?

Wellsense was founded in 2009. It employs 11 to 50 people.

Where is Wellsense based?

Wellsense is headquartered in Birmingham, United States, in the North America region.

How does Wellsense make money?

One revenue line is on record: medical Device Sales.

Who are Wellsense's main competitors?

Direct peers on record are Bruin Biometrics, Leaf Healthcare and EarlySense. Broad incumbents are Mölnlycke Health Care, Smith+Nephew, ConvaTec, 3M Health Care, Coloplast, Baxter International (Hillrom) and Stryker.

Does Wellsense have an API?

No public API is recorded for Wellsense.

What industry is Wellsense in?

Wellsense's product category is Patient Monitoring Medical Devices. Its primary akta.pro industry code is HLAHAIAF, Infusion Pumps (Ambulatory/Stationary), with a secondary code of HLAHAKAB, Peritoneal Dialysis (PD) Systems & Supplies.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DWellSense, Inc. filed a Form D with the SEC on March 22, 2023, announcing an exempt offering of securities under Rule 506(b). The company reported total sales of $1.7 million from 13 investors out of a maximum offering amount of $3 million.SecSEC FORM DWellSense, Inc. filed a Form D with the Securities and Exchange Commission for an exempt offering of securities under Rule 506(b). The company, based in Birmingham, Michigan, has raised $742,608 out of a total offering amount of $1,000,000 from 18 investors. The filing indicates that $100,000 of the proceeds is estimated to be used for payments to executive officers or directors.SecSEC FORM DWellSense, Inc. filed a Form D with the SEC to report an exempt offering of equity securities under Rule 506(b), with total proceeds of $5,000,000. The filing indicates that 36 investors have participated in the offering, which was initiated on August 3, 2021. Proceeds are estimated to include $100,000 allocated for payments to executive officers or directors.PrwebIHI/NPSF Patient Safety Coalition Welcomes WellsenseWellsense, a Michigan-based pressure-injury prevention company, joined the IHI/NPSF Patient Safety Coalition. The coalition cites that over 2.5 million patients develop pressure injuries annually, with 60,000 deaths from complications. Wellsense's visualization system aims to help clinicians identify high-pressure areas.GlobeNewswireResearch Published in WOUNDS Demonstrates Benefits of Continuous Bedside Pressure Mapping in a Pressure Ulcer Prevention Program in ICUA study published in WOUNDS found that continuous bedside pressure mapping with Wellsense's M.A.P. reduced pressure ulcers in ICU patients. Only 0.3% of 307 patients using M.A.P. developed ulcers versus 5% of 320 in a historical control group. The system provides real-time pressure visualization to guide repositioning.GlobeNewswireWellsense Announces Research Presented at SAWC Demonstrates the M.A.P(TM) Helps Hospitals Achieve Their Goal of Zero Pressure UlcersWellsense announced four studies presented at SAWC showing its M.A.P. pressure mapping system helps hospitals achieve zero pressure ulcers. One study at Phoenix VA ICU recorded zero hospital-acquired pressure ulcers in 2012 versus nine in 2011, estimating $657,189 in cost savings. The system provides real-time visual feedback to guide patient repositioning.GlobeNewswireResearch Presented at Tissue Viability Society Meeting Shows Benefits of Using Wellsense's M.A.P(TM) in the Prevention of Pressure UlcersWellsense's M.A.P pressure mapping system was presented at the Tissue Viability Society meeting, showing no new hospital-acquired pressure ulcers in patients at two UK hospitals over six months. The system provides visual feedback to guide repositioning, supporting the NHS's zero-pressure-ulcer goal.GlobeNewswireWellsense Appoints Eitan Machover as Chief Executive OfficerWellsense appointed Eitan Machover as CEO and director, bringing 15 years at GE Healthcare and a decade as a healthcare investor. The company's MAP System monitors pressure to prevent pressure ulcers, which cost over $11.5 billion annually. Machover aims to make the system standard of care across healthcare settings.